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London, United KingdomObjectives The goal of this trial was to study the long-term effects of intravenous (IV) metoprolol administration before
reperfusion on left ventricular (LV) function and clinical events.Background Early IV metoprolol during ST-segment elevation myocardial infarction (STEMI) has been shown to reduce infarct size
when used in conjunction with primary percutaneous coronary intervention (pPCI).Methods The METOCARD-CNIC (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction) trial recruited
270 patients with Killip class II anterior STEMI presenting early after symptom onset (<6 h) and randomized them
to pre-reperfusion IV metoprolol or control group. Long-term magnetic resonance imaging (MRI) was performed on
202 patients (101 per group) 6 months after STEMI. Patients had a minimal 12-month clinical follow-up.Results Left ventricular ejection fraction (LVEF) at the 6 months MRI was higher after IV metoprolol (48.7  9.9% vs.
45.0  11.7% in control subjects; adjusted treatment effect 3.49%; 95% conﬁdence interval [CI]: 0.44% to 6.55%;
p ¼ 0.025). The occurrence of severely depressed LVEF (35%) at 6 months was signiﬁcantly lower in patients
treated with IV metoprolol (11% vs. 27%, p ¼ 0.006). The proportion of patients fulﬁlling Class I indications for
an implantable cardioverter-deﬁbrillator (ICD) was signiﬁcantly lower in the IV metoprolol group (7% vs. 20%,
p ¼ 0.012). At a median follow-up of 2 years, occurrence of the pre-speciﬁed composite of death, heart failure
admission, reinfarction, and malignant arrhythmias was 10.8% in the IV metoprolol group versus 18.3% in the
control group, adjusted hazard ratio (HR): 0.55; 95% CI: 0.26 to 1.04; p ¼ 0.065. Heart failure admission was
signiﬁcantly lower in the IV metoprolol group (HR: 0.32; 95% CI: 0.015 to 0.95; p ¼ 0.046).Conclusions In patients with anterior Killip class II STEMI undergoing pPCI, early IV metoprolol before reperfusion resulted
in higher long-term LVEF, reduced incidence of severe LV systolic dysfunction and ICD indications, and fewer
heart failure admissions. (Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The
METOCARD-CNIC Trial; NCT01311700) (J Am Coll Cardiol 2014;63:2356–62) ª 2014 by the American College
of Cardiology Foundation
Abbreviations
and Acronyms
CI = conﬁdence interval
HR = hazard ratio
ICD = implantable
cardioverter-deﬁbrillator
IV = intravenous
LV = left ventricular
LVEF = left ventricular
ejection fraction
MACE = major adverse
cardiac event(s)
MRI = magnetic resonance
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2357ST-segment elevation myocardial infarction (STEMI) is a
major contributor to mortality and morbidity worldwide (1–3).
Beyond the high mortality rate in the acute phase, STEMI
survivors are at high risk of recurrent events such as congestive
heart failure, arrhythmia, or sudden death. Post-infarction
patients with severely depressed left ventricular ejection frac-
tion (LVEF) are at the highest risk of long-term adverse out-
comes. Pharmacological and nonpharmacological (implantable
cardioverter-deﬁbrillator [ICD]) interventions have greatly
reduced long-term mortality rates in these patients (4,5).
However, the implementation of such strategies represents a
huge economic burden that precludes its universal application.
There is, therefore, a need for additional low-cost therapies to
prevent severe post-infarction left ventricular (LV) dysfunction.See page 2363
imaging
pPCI = primary percutaneous
coronary intervention
STEMI = ST-segment
elevation myocardial
infarctionThe size of the infarct after a STEMI has been revealed as
the main determinant of adverse post-infarction outcomes
(6). Therapies able to reduce infarct size are therefore ur-
gently sought under the hypothesis that smaller infarctions
will result in better long-term heart performance and that
this will translate into fewer adverse clinical events (7,8).
Early intervention with intravenous (IV) metoprolol
before reperfusion (METOCARD-CNIC [Effect of Meto-
prolol in Cardioprotection During an Acute Myocardial
Infarction] trial) was recently shown to signiﬁcantly reduce
infarct size as evaluated by magnetic resonance imaging
(MRI) 1 week post-infarction (9). Here, we present the pre-
speciﬁed evaluation on long-term LVEF (primary MRI
measurement) and the effect on clinical endpoints of the
METOCARD-CNIC trial.
Methods
Study population. The design of the study has been
previously published (10). METOCARD-CNIC was a
multicenter randomized clinical trial in which STEMI pa-
tients undergoing primary percutaneous coronary interven-
tion (pPCI) were randomized to receive IV metoprolol
or control group (no metoprolol) before reperfusion.
Between November 2010 and October 2012, 270 patients
were randomized to IV metoprolol pre-reperfusion (n ¼
139) or control group (n ¼ 131). Inclusion criteria wereFrom the *Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC),
Madrid, Spain; yHospital Universitario Quirón-Universidad Europea de Madrid,
Madrid, Spain; zHospital Montepríncipe, Madrid, Spain; xThe Zena and Michael A.
Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, New
York; kHospital Clínico San Carlos, Madrid, Spain; {Hospital Universitario Central
de Asturias, Oviedo, Spain; #Hospital Clinic, Barcelona, Spain; **Servicio de Urgencia
Médica de Madrid (SUMMA 112), Madrid, Spain; yyServicio de Emergencia Medica
061 de Galicia, Galicia, Spain; zzComplejo Hospitalario Universitario de Vigo-
Meixoeiro, Pontevedra, Spain; xxHospital Universitario Puerta de Hierro, Madrid,
Spain; kkHospital Universitario Doce de Octubre, Madrid, Spain; {{Philips
Healthcare, Madrid, Spain; ##Hospital Universitario León, León, Spain; ***Hospital
de la Princesa, Madrid, Spain; yyyHospital Universitario La Paz, Madrid, Spain; and
the zzzLondon School of Hygiene & Tropical Medicine, London, United Kingdom.
The main sponsor of the METOCARD-CNIC trial was the Centro Nacional de
Investigaciones Cardiovasculares Carlos III (CNIC), through the competitive grantpatient age 18 to 80 years, Killip
class II anterior STEMI, and
anticipated symptom onset-to-
reperfusion time 6 h. Exclusion
criteria were systolic blood pres-
sure persistently <120 mm Hg,
atrioventricular block, heart rate
<60 beats/min, prior infarction,
or active treatment with b-
blockers. Patients randomized to
IV metoprolol received up to 3
5-mg boluses of metoprolol
tartrate. Fifty-ﬁve percent of the
study group was recruited and
treated during ambulance trans-
fer to the hospital. Apart from IV
metoprolol pre-reperfusion (or
control group), all patients re-
ceived state-of-the-art treatment
according to clinical guidelines,
including long-term oral treatment with b-blockers (ﬁrst
dose within 24 h after admission) in all patients with no
contraindication. All patients were treated by local physi-
cians who were blinded to treatment allocation and were
responsible for all clinical actions.
The primary readout of the trial (infarct size evaluated by
MRI performed 1 week post-infarction) was available in 220
patients. The results of the 1-week MRI have been reported
(9): administration of pre-reperfusion IV metoprolol resul-
ted in signiﬁcantly smaller (by 20%) infarcts and with no
excessive side effects.
The study was approved by the ethics committees and
institutional review boards at each participating center, and
all eligible patients gave written informed consent.
Long-term MRI data. The protocol included a follow-up
MRI 6 months after infarction in all patients except for
those who showed no evidence of infarction on baseline
MRI (no detectable gadolinium delayed enhancement). The
detailed MRI protocol and methods for analysis have been
reported (10). Analyses were undertaken by the Centro
Nacional de Investigaciones Cardiovasculares Carlos III
(CNIC) imaging core laboratory by expert researchers
blinded to treatment arm. Data were quantiﬁed using“CNIC translational 01-2009.” Other sponsors were the Spanish Ministry of Health
and Social Policy (EC10-042), the Mutua Madrileña Foundation (AP8695-2011),
and a Master Research Agreement (MRA) between Philips Healthcare and the
CNIC. Dr. Ibanez is a recipient of the ISCIII grants “Fondo de Investigación Sani-
taria” PI10/02268 and PI13/01979 that relate to the topic of this work. The magnetic
resonance images were analyzed with dedicated software (QMass MR version 7.5),
partially supported by a scientiﬁc collaboration with Medis Medical Imaging Systems
BV. Dr. Pizarro, Dr. Fernández-Friera, Ms. Escalera, Mr. García-Prieto, Dr. Mirelis,
Dr. Goicolea, and Dr. Ibanez are members of the Spanish “Red de Investigación
Cardiovascular” (RIC; Program 4: HISPANICVS). Dr. Sánchez-González is an
employee of Philips Healthcare. All other authors have reported that they have no re-
lationships relevant to the contents of this paper to disclose. Drs. Pizarro and Fernández-
Friera contributed equally to this work.
Manuscript received February 19, 2014; revised manuscript received March 6, 2014,
accepted March 6, 2014.
Pizarro et al. JACC Vol. 63, No. 22, 2014
Long-Term Effect of Early Metoprolol in STEMI June 10, 2014:2356–62
2358dedicated software (QMass MR version 7.5, Medis, Leiden,
the Netherlands). At 6-month MRI follow-up, LV volume,
LV mass, LVEF, and the extent of myocardial necrosis
(grams of LV tissue on delayed gadolinium enhancement
images) were determined.
A post-hoc comparison was performed of the between-
group frequencies of long-term LV reduced ejection frac-
tion according to established cutoffs for clinical relevance
(30%, 35%, and 40%) (4).
Evaluation of the indication for ICD implantation.
Given the clinical, social, and economic implications of post-
infarction ICD implantation, we performed a post-hoc
analysis of the rate of ICD indication between study
groups. ICD indication was deﬁned according to Class I
recommendations in current clinical guidelines (4,5): chronic
LVEF 30% or chronic LVEF 30% to 35% in patients
in New York Heart Association functional class II or III.
Clinical endpoints. The pre-speciﬁed clinical endpoint was
the composite of death, readmission because of heart failure,
reinfarction, and malignant ventricular arrhythmias (10).
Clinical follow-up was performed by telephone interview and
access to hospital reports. Once a potential event was detec-
ted, an independent clinical events committee blinded to the
treatment arm reviewed the primary source data and adjudi-
cated the event according to the pre-established protocol.
Statistical methods. The distribution of the continuous
variables was analyzed using graphical methods. For quan-
titative variables, data are expressed as mean  SD and
compared by parametric methods. For categorical data,
percents were compared using exact methods. MRI data
were analyzed between treatment groups by linear regression
models. LVEF was categorized by cutoffs of clinical sig-
niﬁcance, as described in the preceding text. To evaluate
between-group trends, an ordinal regression was performed,
and the proportional odds assumption was then checked.
The survival distributions during follow-up of patients with
and without IV metoprolol treatment were estimated by the
Kaplan-Meier method, followed by the Cox proportional
hazards regression model. The proportional hazards
assumption was conﬁrmed by inspection of Schoenfeld
residuals. Finally, as a pre-speciﬁed outcome, the treatment
effect on the incidence of 1-year follow-up major adverseTable 1 MRI Data (6 Months After Infarction)
IV Metoprolol Group
(n ¼ 101)
Control Group
(n ¼ 101) Dif
LVEDV, ml 187.0  38.8 197.6  45.7 10.6
LVESV, ml 98.2  36.1 112.0  45.0 13.8
LV mass, g 84.6  17.4 86.8  18.1 2.2
Infarcted myocardium, g 15.7  10.5 18.6  11.3 2.8
Infarcted myocardium, % LV 15.7  9.6 18.3  9.8 2.5
LVEF, % 48.7  10.0 45.0  11.7 3.6
Values are mean  SD unless otherwise indicated.
CI ¼ conﬁdence interval; IV ¼ intravenous; LV ¼ left ventricle; LVEDV ¼ left ventricular end-diastoli
MRI ¼ magnetic resonance imaging.cardiac events (MACE) was evaluated by logistic regression.
Treatment effect estimates of all regression models (and 95%
conﬁdence intervals [CIs]) are presented both without and
with adjustment for the 4 stratiﬁcation variables used in
the randomization: time from symptom onset to enrollment
(<1.5 h vs. 1.5 h), diabetes mellitus status, sex, and age
(<60 years vs. 60 years).
Differences were considered statistically signiﬁcant at a
p value <0.05 (2-tailed).
All statistical tests were performed with IBM SPSS Sta-
tistics software, v.20.0 (SPSS, IBM, Armonk, New York)
and Stata 12 (Stata Statistical Software: Release 12, 2011,
StataCorp, College Station, Texas).Results
Long-term MRI data. MRI was scheduled 6 months
after STEMI in all 220 patients undergoing 1-week MRI
except for those with no evidence of infarction in the ﬁrst MRI
study (3 IV metoprolol, 6 control subjects). Nine additional
patients did not undergo follow-up MRI for the following
causes: 1 death (control group), 1 disabling stroke (control
group), 1 technical problem with the MRI (IV metoprolol
group), 1 emigration (IV metoprolol group), and 5 refusals to
undergo follow-up MRI (3 IV metoprolol, 2 control subjects).
Thus, a total of 202 patients underwent 6-month MRI
(101 IV metoprolol and 101 control subjects). Long-term
medication with known beneﬁcial effects on LV remodeling
was similar in both groups of patients (Online Table 1).
MRI data are presented in Table 1. Pre-reperfusion
administration of IV metoprolol resulted in a signiﬁcantly
higher long-term mean LVEF on 6-month MRI (48.7 
9.9% vs. 45.0  11.7% in control patients; adjusted treat-
ment effect 3.49; 95% CI: 0.44% to 6.55%; p ¼ 0.025)
(Fig. 1). LV end-systolic volume was signiﬁcantly lower in
patients treated with pre-reperfusion IV metoprolol (98.1 
36.0 ml vs. 112.0  45.0 ml; adjusted treatment
effect 13.25; 95% CI: 24.47 to 2.03; p ¼ 0.021). The
LVEF values from the 1-week study (9) correlated tightly
with the 6-month values regardless of treatment group
(Online Fig. 1). Long-term extension of scar tissue was
15.7  10.4 g in the IV metoprolol group versus 18.6  11.3Unadjusted
Adjusted
for Stratiﬁcation Variables
ference (95% CI) p Value Difference (95% CI) p Value
2 (22.45 to 1.22) 0.078 10.34 (21.73 to 1.05) 0.075
7 (25.22 to 2.51) 0.017 13.25 (24.47 to 2.03) 0.021
0 (7.15 to 2.75) 0.38 2.09 (6.81 to 2.63) 0.38
9 (6.02 to 0.24) 0.070 2.58 (5.69 to 0.53) 0.10
2 (5.29 to 0.26) 0.075 2.30 (5.09 to 0.49) 0.11
7 (0.64 to 6.71) 0.018 3.49 (0.44 to 6.55) 0.025
c volume; LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ventricular end-systolic volume;
Figure 1 LVEF on MRI 6 Months After Infarction
Left ventricular ejection fraction (LVEF) in patients undergoing magnetic resonance
imaging (MRI) 6 months after infarction. Boxplots represent mean (SEM).
Circles are individual patient data. i.v. ¼ intravenous.
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2359g in the control group (treatment effect 2.89; 95%
CI: 6.02 to 0.24; p ¼ 0.070).
LVEF depression and ICD indications according to
clinical guidelines. The numbers of patients in each
treatment group according to clinically relevant LVEF cut-
offs are illustrated in Figure 2A. The proportion of patients
with depressed LVEF at 6 months was signiﬁcantly lower
in the IV metoprolol group (e.g., 11% vs. 27% withFigure 2 Follow-Up LVEF Categories and Indications for ICD Accordi
(A) Distribution of patients according to LVEF categories. Fisher exact test p ¼ 0.026 an
(Class I recommendation in clinical guidelines) for ICD; see text. Fisher exact test p ¼ 0LVEF 35%, p ¼ 0.006), and the treatment groups also
differed in the distribution of patients by LVEF category.
Treatment allocation to IV metoprolol was associated with
being in a higher LVEF category (common odds ratio 1.84;
95% CI: 1.11 to 3.07; p ¼ 0.019).
The 6-month MRI data were analyzed for formal indi-
cation for ICD implantation according to current clinical
guidelines (4,5) (Fig. 2B). Pre-reperfusion metoprolol
administration resulted in a signiﬁcant reduction of patients
with ICD Class I recommendation (7% vs. 20% in the
control patients, a risk difference of 12.7% [95% CI: 3.2% to
22.3%]; p ¼ 0.012; adjusted odds ratio 0.32; 95% CI: 0.13
to 0.81; p ¼ 0.016). The number needed to treat to avoid
1 ICD indication was 8 (95% CI: 4.5 to 31; p ¼ 0.015).
Clinical follow-up. Median follow-up was 2 years after
STEMI, with all patients but 6 lost to follow-up having a
minimum of 12 months follow-up. The incidence of the
pre-speciﬁed MACE endpoint (composite of death, heart
failure admission, reinfarction, and malignant arrhythmia)
and its individual components by treatment group are
summarized in Table 2. There were fewer numerical MACE
events after pre-reperfusion IV metoprolol administration:
10.8% versus 18.3% in control group (adjusted hazard ratio
[HR]: 0.55; 95% CI: 0.26 to 1.04; p ¼ 0.065). This was
mainly driven by a lower rate of readmission because of heart
failure (2.2% in the IV metoprolol group vs. 6.9% in the
control group; HR: 0.32; 95% CI: 0.015 to 0.95; p¼ 0.046).
Kaplan-Meier curves are shown in Figure 3.
Discussion
This pre-speciﬁed follow-up of the METOCARD-CNIC
trial shows that patients receiving pre-reperfusion IV
metoprolol have a signiﬁcantly higher long-term mean
LVEF compared with control groups and are protectedng to Treatment Allocation
d linear-by-linear association test p ¼ 0.006. (B) Rate of formal indication
.012. NYHA ¼ New York Heart Association; other abbreviations as in Figure 1.
Table 2 Clinical Events
IV Metoprolol Control p Value
MACE 15 (10.8) 24 (18.3) 0.065
Death 6 (4.3) 6 (4.6) 0.92
Cardiac death 3 (2.2) 5 (3.8)
Noncardiac death 3 (2.2) 1 (0.8)
Heart failure admission 3 (2.2) 9 (6.9) 0.046
ICD implantation 2 (1.4) 7 (5.3)
Decompensation 1 (0.7) 3 (2.3)
Re-AMI 1 (0.7) 3 (2.3) 0.15
Malignant ventricular arrhythmia 5 (3.6) 10 (7.7) 0.18
Values are n (%). MACE was the composite of all-cause death, heart failure admission (internal
cardioverter deﬁbrillator [ICD] implantation or clinical decompensation), reinfarction, and malignant
ventricular arrhythmias (ventricular ﬁbrillation/sustained ventricular tachycardia). Values were
adjusted for randomization of variables.
AMI ¼ acute myocardial infarction; IV ¼ intravenous; MACE ¼ major adverse cardiac event(s).
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2360against long-term LVEF depression. These effects were
accompanied by a trend towards reduced hard clinical end-
points. To the best of our knowledge, this is the ﬁrst
demonstration of a pharmacological cardioprotective strategy
used in conjunction with pPCI resulting in sustained ben-
eﬁts on overall LVEF and in a signiﬁcant reduction of cases
of chronic severe LV systolic dysfunction.
The design of the METOCARD-CNIC trial included a
6 months MRI study for the evaluation of the effect of the
therapy on long-term validated prognostic parameters.
MRI is the gold standard for the evaluation of heart
anatomy and function (11). In the 6 months MRI, we
found that besides a higher LVEF, patients in the IV
metoprolol group had signiﬁcantly smaller LV end-systolic
volumes, another well-established post-infarction prog-
nostic parameter (12). We previously reported a signiﬁ-
cantly higher LVEF in the IV metoprolol group in the
1-week post-infarction MRI study (9). As presented, the
LVEF values from the 1-week study correlated tightly withFigure 3 Follow-Up Clinical Endpoints
(A) Kaplan-Meier curves illustrating cumulative incidence of the pre-speciﬁed composite
ventricular arrhythmias. (B) Kaplan-Meier curves showing the cumulative incidence of rea
i.v. ¼ intravenous; MACE ¼ major adverse cardiac events.the follow-up values in both groups of treatment,
supporting the conclusion that the long-term beneﬁts of
pre-reperfusion IV metoprolol are a consequence of the
short-term beneﬁcial effects detected at 1 week post-
infarction. In order to determine whether the attrition of
patients between the 1-week and 6-month MRI studies
could have biased the results reported here, we evaluated
the 1-week MRI LVEF in those patients who underwent
the ﬁrst scan, but not the 6-month follow-up (n ¼ 18):
median (ﬁrst and third quartile) LVEF values were 53.0%
(45.5% to 59.0%) in the IV metoprolol group versus 52.5%
(46.8% to 62.0%) in the control group, excluding the
possibility of selection bias introduced by patient attrition
between 1-week and follow-up MRIs.
The long-term beneﬁcial effects of pre-reperfusion IV
metoprolol on LVEF were associated with a nonsigniﬁcant
trend toward reduced hard clinical endpoints. The main
limitation for the interpretation of this ﬁnding is that our
trial was not powered to detect differences in clinical events.
Other small trials testing the effect of cardioprotective
strategies in STEMI have reported a signiﬁcant reduction in
long-term events despite being underpowered. In the
CONDI (Remote Ischemic Conditioning in Primary PCI)
trial, Sloth et al. (13) found that remote ischemic condi-
tioning in STEMI seemed to improve long-term clinical
outcomes. Their minimum follow-up was 3 years, whereas
ours was 12months. In fact, the survival curves in theCONDI
trial showed a clear divergence after 2 years of follow-up. In a
different study, Stone et al. (14) found that intracoronary
abciximab in anterior STEMI resulted in a signiﬁcant events
reduction in the non–pre-speciﬁed time range (30 days to
12 months) post-infarction. Given the strong trend towards
events reduction found in our trial, it is plausible that longer
follow-up will reveal statistically signiﬁcant differences.
Similarly, non–pre-speciﬁed analyses of our study showedof death, admission as a result of heart failure (HF), reinfarction, or malignant
dmission as a result of heart failure. CI ¼ conﬁdence interval; HR ¼ hazard ratio;
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2361statistical signiﬁcance (heart failure admission HR: 0.32;
p ¼ 0.046). However, we feel that these non-powered or
non–pre-speciﬁed analyses are of limited value even when
statistical signiﬁcance is shown.We believe that our data form
a sufﬁcient basis for a larger STEMI clinical trial of early IV
metoprolol powered for clinical events reduction.
The implementation of reperfusion strategies over the past
decades has signiﬁcantly reduced the acute mortality associ-
ated with STEMI (15). However, a high proportion of sur-
vivors remain at high risk of future cardiovascular events
throughout life, including sudden death and repetitive epi-
sodes of heart failure. Long-term post-infarction LV systolic
function is a major predictor of these clinical events; indeed,
LVEF remains the principal objective parameter used for the
indication for post-infarction heart failure therapies (4,5).
Extensive clinical research has led to chronic heart failure
interventions (pharmacological and device-based) that reduce
long-term mortality in STEMI survivors with low LVEF
(4,5). Nonetheless, the implementation of these strategies
comes at a high socioeconomic cost (16,17). The enormous
economic burden for health services is the main factor pre-
venting universal implementation of these new heart failure
therapies (18,19), and most countries in development cannot
afford them (20), despite having implemented reperfusion
strategies for STEMI. Even in advanced economies, eco-
nomic considerations prevent universal use of the most
expensive therapies (ICD and cardiac resynchronization de-
vices) (21,22). The present trial demonstrates that adminis-
tration of a low-cost therapy (<2V in Spain, <$3 in the
United States) results in higher long-term LVEF. Although
the observed 3.7-point absolute difference in mean LVEF
could be judged as small, the much lower number of patients
with severely depressed LVEF in the treatment group is more
clinically relevant, and would translate into a greater socio-
economic impact. Furthermore, the number of patients
with a formal indication for ICD implantation according to
clinical guidelines was two-thirds less among the IV meto-
prolol patients. Overall, the rate of actual ICD implantation
among cases with a formal indication was 33% (9 of 27,
Table 2). This rate of ICD implantation is in agreement with
other dedicated studies (rate between 30% and 35%) (23,24),
and above what is seen in the general population (around
13%) (25).
In the ﬁrst report on the METOCARD-CNIC trial, we
documented an average 20% smaller infarct size in patients
randomized to IV metoprolol, as evaluated by MRI 1 week
after infarction (9). At 6 months, total infarct size difference
between groups had been attenuated (15.6 g in the IV
metoprolol group vs. 18.6 g in the control group, p ¼ 0.07).
Thus, despite the infarct size still beingz17% smaller in the
active treatment group, the natural shrinkage of scar tissue
narrowed the absolute difference (26). It is also important
to consider that this trial was powered to detect differences
in infarct size in the acute phase (1 week after STEMI).
Beta-blockers have been shown to reduce mortality when
used as secondary prevention after infarction (27), and are anestablished part of the pharmacological armamentarium,
with a Class I indication in clinical guidelines (1,2). How-
ever, very early IV administration before reperfusion is not
encouraged, mainly because of the results of the COMMIT
(Efﬁcacy and Safety of Adding Clopidogrel to Aspirin or
Use of Metoprolol in Myocardial Infarction) trial, which
showed no short-term net clinical beneﬁt of early metoprolol
in STEMI patients undergoing thrombolysis (28). The
COMMIT trial recruited all comers with almost no re-
striction. By contrast, the METOCARD-CNIC trial
recruited Killip class II patients presenting with systolic
blood pressure 120 mmHg, heart rate 60 beats/min, and
reperfused by pPCI within 6 h of infarct onset. Subgroup
analyses of the COMMIT trial (28) suggested that patients
ﬁtting the inclusion criteria of the METOCARD-CNIC
trial beneﬁted from early IV metoprolol in terms of mor-
tality reduction. In addition, the clinical beneﬁts associated
with infarct size reduction (and post-infarction LVEF
improvement) are expected to occur late (months to years)
after STEMI (13,29). In the COMMIT trial, clinical
follow-up was <1 month. It is plausible that longer follow-
up of the COMMIT trial would show additional beneﬁt of
early IV metoprolol in survivors. Thus, an important lesson
from the COMMIT trial is that not all STEMI patients
beneﬁt from very early IV metoprolol, a deduction supported
by the results reported here.
Study limitations. This trial was not powered to detect
differences in hard clinical endpoints, and thus, the results
on this outcome should be taken with caution.
Conclusions
Intravenous metoprolol administered before reperfusion re-
sults in higher long-term LVEF and a lower incidence of
post-infarction severe LVEF depression in anterior STEMI
patients undergoing primary PCI during the ﬁrst 6 h of
infarction. This low-cost therapy could have an important
socioeconomic impact by reducing the number of patients
requiring expensive interventions to treat post-infarction
heart failure and prevent sudden death. The results of the
METOCARD-CNIC trial warrant a large study powered
to detect differences in hard clinical endpoints.
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